Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

Phase 2

Completed

• Conditions: Asthma; Mild Asthma

• Registration Number: NCT00380354
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2006-09-21
• Study First Submitted QC: 2006-09-21
• Study First Posted: 2006-09-25
• Study Completion: 2007-06
• Status Verified: 2011-02
• Last Update Submitted: 2012-05-31
• Last Update Posted: 2012-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Asthmatic response	after 7 days of treatment

Secondary Outcome Measures

Name	Time	Method
FEV1 Concentration of exhaled nitric oxide	on day 8 of each treatment period
Incidence of treatment emergent adverse events	throughout study

Trial Locations

Locations (1)

GSK Investigational Site; 🇬🇧 London, United Kingdom